Pfizer Corporation

Beecham Group Plc

Other

Smithkline Beecham Corporation

Brian Charles Gasson

George Burton

Desmond John Best

Stephen C Fell

David John Payne

Michael J Pearson

David Richard Witty

John Hargreaves Bateson

Neal Frederick Osborne

George R Burton

Graham Walker

Jeremy D Hinks

There is provided a process for the preparation of a compound according to Formula (II): which includes the step of cyclizing a compound of Formula (III): wherein R, R, R, R, X and m have meanings which are given in the description.

Process for the preparation of cephalosporin compounds and synthetic intermediates

Compounds of formula (I) or salts thereof: ##STR1## wherein R.sup.1 is hydrogen, methoxy or formamido; R.sup.2 is an acyl group; CO.sub.2 R.sup.3 is a carboxy group or a carboxylate anion, or R.sup.3 is a carboxy protecting group, pharmaceutically acceptable salt-forming group or in vivo hydrolysable ester group; R.sup.4 represents hydrogen or up to four substituents; X is O, S, SO or SO.sub.2 ; Y is O, S, SO or SO.sub.2 ; n is 0 or 1; and m is 1 or 2. The compounds have antibacterial activity. Methods of synthesis of, and pharmaceutical formulations containing, compounds (I) are also described.

2-isocephem and oxacephem derivatives and use as antibacterial agents

.beta.-thiopropionyl-aminoacid derivatives and their use as

2-isocephem and oxacephem derivatives, and use as antibacterial agents

.beta.-Lactam compounds of the formula (I) including pharmaceutically acceptable salts and in vivo hydrolysable esters, processes for their preparation and their use as antibiotics: ##STR1## wherein R.sup.1 is hydrogen, methoxy or formamido;

Cephalosporin derivatives and pharmaceutical compositions

The present invention provides a compound of formula (I) or a pharmaceutically acceptable salt or in-vivo hydrolysable ester thereof: ##STR1## wherein R.sup.1 is a 5 or 6 membered sulphur and/or nitrogen containing heterocyclic group substituted by an optionally protected amino group, with the proviso that R.sup.1 is not 2-aminothiazol-4-yl, and R is hydrogen; optionally substituted C.sub.1-12 alkyl; optionally substituted C.sub.2-12 alkenyl or alkynyl; carbocyclyl; aryl or heterocyclyl. These compounds have antibacterial properties, and therefore are of use in the treatment of bacterial infections in humans and animals caused by a wide range of organizations.

Heterocyclic substituted penicillin antibiotics

The compound of the formula (I): ##STR1## and salts and esters thereof may be used as a .beta.-lactamase inhibitor to enhance the effectiveness of penicillins or cephalosporins.

Derivatives of clavulanic acid, a process for their preparation and

The compound of the formula (I): ##STR1## and pharmaceutically acceptable salts and esters thereof, are useful for their .beta.-lactamase inhibitory activity and synergized penicillins and cephalosporins in the treatment of bacterial infections.

Aminocarbonylmethyl ethers of clavulanic acid, a process for their

Growing community of inventors

Redhill, United Kingdom

Brian Charles Gasson